Trial Profile
Phase II randomized controlled trial of epirubicin hydrochloride and miriplatin hydrate as anticancer agents for transcatheter arterial chemoembolization of hepatocellular carcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 May 2016
Price :
$35
*
At a glance
- Drugs Epirubicin (Primary) ; Miriplatin (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms HCC-Epirubicin&Miriplatin-P-II
- 24 Sep 2013 New trial record